Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively ...

MAJESTY, the first global Phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years –– Up to 30% of people with membranous nephropathy progress to ...

Kochi: High court on Monday replaced the Kochi city police commissioner with the Ernakulam range DIG to head the SIT (special investigation team) prob.

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient ...

Fourth quarter and full year 2025 total revenue of $192.6 million and $616.3 million, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively Target guidance of approxima ...

Neuromuscular disease refers to a group of heterogeneous disorders that impair the function of motor nerves, muscles or neuromuscular junctions. Symptoms can include muscle pain, weakness or atrophy, ...

Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal demyelinating disease of the central nervous system (CNS) caused by the reactivation of the JC polyomavirus (JCPyV). While ...

Stroke is the second leading cause of death worldwide and a complex, heterogeneous condition. In this review, we provide an overview of the current knowledge on monogenic and multifactorial forms of ...

Small vessel disease is a disorder of cerebral microvessels that causes white matter hyperintensities and several other common abnormalities (eg, recent small subcortical infarcts and lacunes) seen on ...